可疑甲状腺球蛋白增高性分化型甲状腺癌患者经<sup>131</sup>I治疗后的临床转归

郭文婷; 慕转转; 李征; 张迎强; 靳晓娜; 林岩松

doi:10.19401/j.cnki.1007-3639.2022.05.006

您当前的位置：

首页 >

文章列表页 >

可疑甲状腺球蛋白增高性分化型甲状腺癌患者经¹³¹I治疗后的临床转归

论著 | 更新时间：2025-12-31

- 可疑甲状腺球蛋白增高性分化型甲状腺癌患者经¹³¹I治疗后的临床转归
- Clinical outcome of ¹³¹I therapy in differentiated thyroid cancer patients with suspicious high thyroglobulin concentration
- 中国癌症杂志 2022年32卷第5期页码：410-416
- 作者机构：
  
  1. 中国医学科学院北京协和医学院北京协和医院医学科学研究中心,疑难重症及罕见病国家重点实验室,北京 100730
  2. 中国医学科学院北京协和医学院北京协和医院核医学科,疑难重症及罕见病国家重点实验室,北京 100730
  3. 核医学分子靶向诊疗北京市重点实验室,北京 100730
  4. 北京核工业医院核素诊疗中心,北京 102413
- 作者简介：
  
  [ "郭文婷（ORCID: 0000-0002-9097-2828）,博士,研究实习员 E-mail: wtcandy@126.com" ]
  林岩松（ORCID: 0000-0001-6095-4728）,博士,主任医师、教授,中国医学科学院北京协和医学院北京协和医院核医学科副主任 E-mail: linyansong1968@163.com
- 基金信息：
  
  国家重点研发计划“政府间国际科技创新合作/港澳台科技创新合作”重点专项(2019YFE0106400);中国医学科学院中央级公益性科研院所基本科研业务费专项资金(2019XK320009);中国医学科学院医学与健康科技创新工程(2020-I2M-2-003)
- DOI：10.19401/j.cnki.1007-3639.2022.05.006
  中图分类号： R736.1
- 收稿：2022-04-18，
  
  修回：2022-05-02，
  
  纸质出版：2022-05-30
- 稿件说明：
移动端阅览
郭文婷, 慕转转, 李征, 等. 可疑甲状腺球蛋白增高性分化型甲状腺癌患者经¹³¹I治疗后的临床转归[J]. 中国癌症杂志, 2022,32(5):410-416.

Wenting GUO, Zhuanzhuan MU, Zheng LI, et al. Clinical outcome of ¹³¹I therapy in differentiated thyroid cancer patients with suspicious high thyroglobulin concentration[J]. China Oncology, 2022, 32(5): 410-416.
郭文婷, 慕转转, 李征, 等. 可疑甲状腺球蛋白增高性分化型甲状腺癌患者经¹³¹I治疗后的临床转归[J]. 中国癌症杂志, 2022,32(5):410-416. DOI： 10.19401/j.cnki.1007-3639.2022.05.006.

Wenting GUO, Zhuanzhuan MU, Zheng LI, et al. Clinical outcome of ¹³¹I therapy in differentiated thyroid cancer patients with suspicious high thyroglobulin concentration[J]. China Oncology, 2022, 32(5): 410-416. DOI： 10.19401/j.cnki.1007-3639.2022.05.006.

摘要

背景与目的：

分化型甲状腺癌（differentiated thyroid cancer

DTC）中可疑甲状腺球蛋白（thyroglobulin

Tg）水平增高但无明确结构性病灶者预后差异大

临床治疗决策存在较大争议

本研究拟探究

131

I治疗及不同治疗剂量对于这类患者临床转归的影响。

方法：

回顾并分析2007

#x02014;2021年就诊于北京协和医院核医学科的138例DTC全切术后可疑Tg水平增高的患者

依据首次

131

I治疗剂量分为低（剂量为1.11 GBq）、中（1.11 GBq

剂量

#x02264;3.70 GB

q）、高（3.70 GBq

剂量

#x02264;7.40 GBq）3组

观察不同剂量

131

I治疗后6个月的短期及后续未再行其他干预患者的长期疗效

并进一步观察经初始治疗评估为生化疗效不佳（biochemical incomplete response

BIR）患者的临床转归。采用受试者工作特征（receiver operating characteristic

ROC）曲线评估预测结构性疗效不佳（structural incomplete response

SIR）和远处转移的刺激性Tg（stimulated Tg

sTg）的最佳界值点。

结果：

低、中、高3个剂量组中分别有6.7%、13.5%、7.0%的患者短期疗效达到疗效满意（excellent response

ER）

3组间总体疗效差异无统计学意义（

=1.02

=0.60）。常规随访下3组患者的长期疗效同样差异无统计学意义（

=2.94

=0.23）。经初始治疗评估为BIR的患者经常规随访和再次

131

I治疗后的临床转归差异无统计学意义（

=324.5

=0.15）。预测SIR和远处转移的sTg最佳界值点分别为27.5和61.7 ng/mL。

结论：

可疑Tg水平增高的DTC患者复发率较高

以27.5 ng/mL为sTg界值点有助于尽早识别这部分患者。

131

I治疗有助于术后可疑Tg水平增高患者快速达到ER

但高剂量

131

I治疗未对患者的预后产生增益效应;再次

131

I治疗对于BIR患者未显示出进一步获益。

Abstract

Background and purpose:

The prognosis of differentiated thyroid cancer (DTC) patients with suspicious high thyroglobulin (Tg) concentration and without explicit structural lesions varies from each other

hence the clinical treatment decisions including

131

I therapy remain controversial. This study aimed to explore the effects of

131

I treatment and the therapeutic dose on the clinical outcome of these patients.

Methods:

The study included 138 DTC patients treated in Department of Nuclear Medicine

Peking Union Medical College Hospital from 2007 to 2021

who had undergone total thyroidectomy and subsequent

131

I therapy. All patients were divided into 3 groups as low dose (dose=1.11 GBq)

medium dose (1.11 GBq

dose

#x02264;3.70 GBq) and high dose (3.70 GBq

dose

#x02264;7.40 GBq) according to the dose of

131

I therapy. We compared the short-term and end-of period response to therapy among these three groups

and further observed the clinical outcome of patients with biochemical incomplete response (BIR) after initial treatment. The

receiver operating characteristic (ROC) curve was employed to evaluate the predictive value of stimulated Tg (sTg) levels in patients with structural incomplete response (SIR) and distant metastasis.

Results:

For the short-term response

the rate of excellent response (ER) was 6.7%

13.5% and 7.0% in low

medium and high dose group

respectively. The short-term response showed no statistically significant difference among three groups (

=1.02

=0.60). The end-of-period response among the three groups under routine follow-up also showed no significant difference (

=2.94

=0.23). No significant difference was observed in the clinical outcome of patients with BIR after routine follow-up and second

131

I treatment (

=324.5

=0.15). The diagnostic critical point (DCP) of sTg to predict SIR and distant metastasis was 27.5 and 61.7 ng/mL

respectively.

Conclusion:

DTC patients with suspicious high Tg concentration has high recurrence risk

taking 27.5 ng/mL as the cut-off of sTg is helpful to identify the patients with high recurrence risk early.

131

I treatment is helpful for these patients to achieve ER as soon as possible. However

high-dose

131

I did not have greater benefits on the prognosis of these patients. Second

131

I treatment showed no further benefit for BIR patients.

关键词

Keywords

references

TUTTLE R M , LEBOEUF R . Follow up approaches in thyroid cancer: a risk adapted paradigm [J ] . Endocrinol Metab Clin N Am , 2008 , 37 ( 2 ): 419 - 435 ,, ix-x. DOI: 10.1016/j.ecl.2008.02.008 http://doi.org/10.1016/j.ecl.2008.02.008 https://linkinghub.elsevier.com/retrieve/pii/S0889852908000121 https://linkinghub.elsevier.com/retrieve/pii/S0889852908000121

TUTTLE R M , TALA H , SHAH J , et al . Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system [J ] . Thyroid , 2010 , 20 ( 12 ): 1341 - 1349 . DOI: 10.1089/thy.2010.0178 http://doi.org/10.1089/thy.2010.0178 https://www.liebertpub.com/doi/10.1089/thy.2010.0178 https://www.liebertpub.com/doi/10.1089/thy.2010.0178

HAUGEN B R , ALEXANDER E K , BIBLE K C , et al . 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer [J ] . Thyroid , 2016 , 26 ( 1 ): 1 - 133 . DOI: 10.1089/thy.2015.0020 http://doi.org/10.1089/thy.2015.0020 https://www.liebertpub.com/doi/10.1089/thy.2015.0020 https://www.liebertpub.com/doi/10.1089/thy.2015.0020

丁勇 , 马庆杰 , 王任飞 , 等 . 分化型甲状腺癌术后 131 I治疗前评估专家共识 [J ] . 中国癌症杂志 , 2019 , 29 ( 10 ): 832 - 840 .

DING Y , MA Q J , WANG R F , et al . Expert consensus on preoperative evaluation of 131 I after surgery for differentiated thyroid cancer [J ] . China Oncol , 2019 , 29 ( 10 ): 832 - 840 .

ALZAHRANI A S , MOHAMED G , AL SHAMMARY A , et al . Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer [J ] . J Endocrinol Invest , 2005 , 28 ( 6 ): 540 - 546 . DOI: 10.1007/BF03347243 http://doi.org/10.1007/BF03347243 http://link.springer.com/10.1007/BF03347243 http://link.springer.com/10.1007/BF03347243

CASTAGNA M G , TALA JURY H P , CIPRI C , et al . The use of ultrasensitive thyroglobulin assays reduces but does not abolish the need for TSH stimulation in patients with differentiated thyroid carcinoma [J ] . J Endocrinol Invest , 2011 , 34 ( 8 ): e219 - e223 .

VAISMAN F , MOMESSO D , BULZICO D A , et al . Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy [J ] . Clin Endocrinol (Oxf) , 2012 , 77 ( 1 ): 132 - 138 . DOI: 10.1111/j.1365-2265.2012.04342.x http://doi.org/10.1111/j.1365-2265.2012.04342.x https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2265.2012.04342.x https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2265.2012.04342.x

SZUMOWSKI P , ABDELRAZEK S , IWANICKA D , et al . Dosimetry during adjuvant 131 I therapy in patients with differentiated thyroid cancer-clinical implications [J ] . Sci Rep , 2021 , 11 ( 1 ): 13930 . DOI: 10.1038/s41598-021-93431-1 http://doi.org/10.1038/s41598-021-93431-1 https://doi.org/10.1038/s41598-021-93431-1 https://doi.org/10.1038/s41598-021-93431-1

CAMPENNÌ A , GIOVANELLA L , PIGNATA S A , et al . Thyroid remnant ablation in differentiated thyroid cancer: searching for the most effective radioiodine activity and stimulation strategy in a real-life scenario [J ] . Nucl Med Commun , 2015 , 36 ( 11 ): 1100 - 1106 . DOI: 10.1097/MNM.0000000000000367 http://doi.org/10.1097/MNM.0000000000000367 https://journals.lww.com/00006231-201511000-00005 https://journals.lww.com/00006231-201511000-00005

YANG X , LIANG J , LI T J , et al . Preablative stimulated thyroglobulin correlates to new therapy response system in differentiated thyroid cancer [J ] . J Clin Endocrinol Metab , 2016 , 101 ( 3 ): 1307 - 1313 . DOI: 10.1210/jc.2015-4016 http://doi.org/10.1210/jc.2015-4016 https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2015-4016 https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2015-4016

YANG X , LIANG J , LI T J , et al . Postoperative stimulated thyroglobulin level and recurrence risk stratification in differentiated thyroid cancer [J ] . Chin Med J (Engl) , 2015 , 128 ( 8 ): 1058 - 1064 .

TUTTLE R M . Optimal management of a biochemical incomplete response to therapy in differentiated thyroid cancer: aggressive treatment or cautious observation? [J ] . Endocrine , 2014 , 46 ( 3 ): 363 - 364 . DOI: 10.1007/s12020-014-0213-2 http://doi.org/10.1007/s12020-014-0213-2 http://link.springer.com/10.1007/s12020-014-0213-2 http://link.springer.com/10.1007/s12020-014-0213-2

慕转转 , 李征 , 张鑫 , 等 . 经验性 131 I治疗对甲状腺乳头状癌不摄碘肺转移患者价值存疑 [J ] . 中国癌症杂志 , 2020 , 30 ( 12 ): 991 - 995 .

浏览量

3080

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

中低危分化型甲状腺癌低剂量¹³¹I治疗后短期转归的临床分析

诊断性¹³¹I全身显像在分化型甲状腺癌¹³¹I治疗决策中的作用

治疗前刺激性甲状腺球蛋白阴性合并淋巴结转移的分化型甲状腺癌¹³¹I治疗后的临床转归

分化型甲状腺癌被膜及被膜外微小侵犯与复发风险

《2025版美国甲状腺学会成人分化型甲状腺癌管理指南》解读：分化型甲状腺癌的外照射放疗进展

可疑甲状腺球蛋白增高性分化型甲状腺癌患者经131I治疗后的临床转归

Clinical outcome of 131I therapy in differentiated thyroid cancer patients with suspicious high thyroglobulin concentration

DOI：10.19401/j.cnki.1007-3639.2022.05.006

摘要

Abstract

关键词

Keywords

references

可疑甲状腺球蛋白增高性分化型甲状腺癌患者经¹³¹I治疗后的临床转归

Clinical outcome of ¹³¹I therapy in differentiated thyroid cancer patients with suspicious high thyroglobulin concentration